0
0
Home » Pharmaceuticals

Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Non-Hodgkin lymphoma is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms may include night sweats, fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath. Treatment includes surgery, radiation therapy, and chemotherapy.

The Non-Hodgkin Lymphoma drugs in development market research report provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects.

What are the key targets of the Non-Hodgkin Lymphoma pipeline drugs market?

Some of the targets of the Non-Hodgkin Lymphoma pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Tyrosine Protein Kinase BTK, Cells Expressing B Cell Receptor CD22, Programmed Cell Death Protein 1, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Leukocyte Surface Antigen CD47, CD3, and Programmed Cell Death 1 Ligand 1.

Non-Hodgkin Lymphoma pipeline drugs market, by targets

Non-Hodgkin Lymphoma pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the Non-Hodgkin Lymphoma pipeline drugs market?

The mechanisms of action of the Non-Hodgkin Lymphoma pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Leukocyte Surface Antigen CD47 Inhibitor, CD3 Agonist, and Programmed Cell Death 1 Ligand 1 Inhibitor.

Non-Hodgkin Lymphoma pipeline drugs market, by mechanisms of action

Non-Hodgkin Lymphoma pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Non-Hodgkin Lymphoma pipeline drugs market?

The routes of administration in the Non-Hodgkin Lymphoma pipeline drugs market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, topical, intramuscular, intralesional, and intradermal.

Non-Hodgkin Lymphoma pipeline drugs market, by routes of administration

Non-Hodgkin Lymphoma pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Non-Hodgkin Lymphoma pipeline drugs market?

The molecule types in the Non-Hodgkin Lymphoma pipeline drugs market are small molecule, gene-modified cell therapy, monoclonal antibody, monoclonal antibody conjugated, cell therapy, fusion protein, recombinant protein, synthetic peptide, subunit vaccine, and oligonucleotide.

Non-Hodgkin Lymphoma pipeline drugs market, by molecule types

Non-Hodgkin Lymphoma pipeline drugs market, by molecule types

For more molecule types insights, download a free report sample

Which are the key companies in the Non-Hodgkin Lymphoma pipeline drugs market?

Some of the key companies in the Non-Hodgkin Lymphoma pipeline drugs market are Bristol-Myers Squibb Co, AstraZeneca Plc, Novartis AG, Gilead Sciences Inc, AbbVie Inc, F. Hoffmann-La Roche Ltd, Gracell Biotechnologies Inc, Pfizer Inc, Bayer AG, and BeiGene Ltd.

Non-Hodgkin Lymphoma pipeline drugs market, by key companies

Non-Hodgkin Lymphoma pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Tyrosine Protein Kinase BTK, Cells Expressing B Cell Receptor CD22, Programmed Cell Death Protein 1, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Leukocyte Surface Antigen CD47, CD3, and Programmed Cell Death 1 Ligand 1
Mechanisms of Action Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Leukocyte Surface Antigen CD47 Inhibitor, CD3 Agonist, and Programmed Cell Death 1 Ligand 1 Inhibitor
Routes of Administration Intravenous, Oral, Parenteral, Subcutaneous, Intratumor, Intravenous Drip, Topical, Intramuscular, Intralesional, and Intradermal
Molecule Types Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Fusion Protein, Recombinant Protein, Synthetic Peptide, Subunit Vaccine, and Oligonucleotide
Key Companies Bristol-Myers Squibb Co, AstraZeneca Plc, Novartis AG, Gilead Sciences Inc, AbbVie Inc, F. Hoffmann-La Roche Ltd, Gracell Biotechnologies Inc, Pfizer Inc, Bayer AG, and BeiGene Ltd

This report provides:

  • A snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
  • Reviews of pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • Evaluation of Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Key Players

3SBio Inc

4SC AG

A. Menarini Industrie Farmaceutiche Riunite Srl .

AB Science SA

AbbVie Inc

ABIONYX Pharma SA..

Abologix Sarl

Acerta Pharma BV

Actinium Pharmaceuticals Inc

Actinobac Biomed Inc

Adagene Suzhou Ltd

ADC Therapeutics SA

Adicet Bio Inc

Adienne Pharma & Biotech SA

Adlai Nortye Biopharma Co Ltd

Advenchen Laboratories LLC

Table of Contents

Table of Contents

Introduction

Non-Hodgkin Lymphoma – Overview

Non-Hodgkin Lymphoma – Therapeutics Development

Non-Hodgkin Lymphoma – Therapeutics Assessment

Non-Hodgkin Lymphoma – Companies Involved in Therapeutics Development

Non-Hodgkin Lymphoma – Drug Profiles

Non-Hodgkin Lymphoma – Dormant Projects

Non-Hodgkin Lymphoma – Discontinued Products

Non-Hodgkin Lymphoma – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Non-Hodgkin Lymphoma, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Non-Hodgkin Lymphoma – Pipeline by 3SBio Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by 4SC AG, 2021

Non-Hodgkin Lymphoma – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2021

Non-Hodgkin Lymphoma – Pipeline by AB Science SA, 2021

Non-Hodgkin Lymphoma – Pipeline by AbbVie Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by ABIONYX Pharma SA, 2021

Non-Hodgkin Lymphoma – Pipeline by Abologix Sarl, 2021

Non-Hodgkin Lymphoma – Pipeline by Acerta Pharma BV, 2021

Non-Hodgkin Lymphoma – Pipeline by Actinium Pharmaceuticals Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Actinobac Biomed Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Adagene Suzhou Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by ADC Therapeutics SA, 2021

Non-Hodgkin Lymphoma – Pipeline by Adicet Bio Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Adienne Pharma & Biotech SA, 2021

Non-Hodgkin Lymphoma – Pipeline by Adlai Nortye Biopharma Co Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Advenchen Laboratories LLC, 2021

Non-Hodgkin Lymphoma – Pipeline by Affimed GmbH, 2021

Non-Hodgkin Lymphoma – Pipeline by Affitech A/S, 2021

Non-Hodgkin Lymphoma – Pipeline by AGC Biologics SpA, 2021

Non-Hodgkin Lymphoma – Pipeline by AI Therapeutics Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Akeso Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Aleta Biotherapeutics Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Alexion Pharmaceuticals Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Alfasigma SpA, 2021

Non-Hodgkin Lymphoma – Pipeline by Allogene Therapeutics Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Alphamab Oncology, 2021

Non-Hodgkin Lymphoma – Pipeline by Alpine Immune Sciences Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by ALX Oncology Holdings Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Amgen Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Anew Oncology Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Angimmune LLC, 2021

Non-Hodgkin Lymphoma – Pipeline by Angiocrine Bioscience Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Anhorn Medicines Co Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Antengene Corp Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by AP Biosciences Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Apollomics Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Apotex Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Applied Therapeutics Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Aprea Therapeutics Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Archigen Biotech Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Arcus Biosciences Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Ardan Pharma, 2021

Non-Hodgkin Lymphoma – Pipeline by Argenx SE, 2021

Non-Hodgkin Lymphoma – Pipeline by Ascentage Pharma Group International, 2021

Non-Hodgkin Lymphoma – Pipeline by Astellas Pharma Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Astex Pharmaceuticals Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by AstraZeneca Plc, 2021

Non-Hodgkin Lymphoma – Pipeline by AUM Biosciences Pte Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Aurigene Discovery Technologies Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Autolus Therapeutics Plc, 2021

Non-Hodgkin Lymphoma – Pipeline by Avalon GloboCare Corp, 2021

Non-Hodgkin Lymphoma – Pipeline by Avesthagen Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Avipep Pty Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by AVM Biotechnology LLC, 2021

Non-Hodgkin Lymphoma – Pipeline by AzarGen Biotechnologies (Pty) Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by BAKX Therapeutics Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Bantam Pharmaceutical LLC, 2021

Non-Hodgkin Lymphoma – Pipeline by Bayer AG, 2021

Non-Hodgkin Lymphoma – Pipeline by BeiGene Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Beijing Cytoheal Biotech Co Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Beijing Gaobo Biotechnology Co Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Beijing GD Initiative Cell Therapy Technology Co Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Celularity Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Elicera Therapeutics AB, 2021

Non-Hodgkin Lymphoma – Pipeline by Emmaus Life Sciences Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Enterome Bioscience SA, 2021

Non-Hodgkin Lymphoma – Pipeline by Epidestiny Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Epizyme Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by ERYTECH Pharma SA, 2021

Non-Hodgkin Lymphoma – Pipeline by Esanex Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Eternity Bioscience Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Eucure (Beijing) Biopharma Co Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Eureka Therapeutics Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Eutilex Co Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Evive Biotech, 2021

Non-Hodgkin Lymphoma – Pipeline by Evotec SE, 2021

Non-Hodgkin Lymphoma – Pipeline by Excelmab Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Magenta Therapeutics Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by ManysmarT Therapeutics Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Marino Biotechnology Co Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Marker Therapeutics Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Meabco AS, 2021

Non-Hodgkin Lymphoma – Pipeline by MedC Biopharma Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Medinet Co Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by MediSix Therapeutics Pte Ltd, 2021

Non-Hodgkin Lymphoma – Pipeline by Meditope Biosciences Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by Medivir AB, 2021

Non-Hodgkin Lymphoma – Pipeline by MedPacto Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by MEI Pharma Inc, 2021

Non-Hodgkin Lymphoma – Pipeline by MENTRIK Biotech LLC, 2021

Non-Hodgkin Lymphoma – Pipeline by Merck & Co Inc, 2021

List of Figures

List of Figures

Number of Products under Development for Non-Hodgkin Lymphoma, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

Frequently Asked Questions

Some of the targets of the Non-Hodgkin Lymphoma pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Tyrosine Protein Kinase BTK, Cells Expressing B Cell Receptor CD22, Programmed Cell Death Protein 1, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Leukocyte Surface Antigen CD47, CD3, and Programmed Cell Death 1 Ligand 1.

The mechanisms of action of the Non-Hodgkin Lymphoma pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Leukocyte Surface Antigen CD47 Inhibitor, CD3 Agonist, and Programmed Cell Death 1 Ligand 1 Inhibitor.

The routes of administration in the Non-Hodgkin Lymphoma pipeline drugs market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, topical, intramuscular, intralesional, and intradermal.

The molecule types in the Non-Hodgkin Lymphoma pipeline drugs market are small molecule, gene-modified cell therapy, monoclonal antibody, monoclonal antibody conjugated, cell therapy, fusion protein, recombinant protein, synthetic peptide, subunit vaccine, and oligonucleotide.

Some of the key companies in the Non-Hodgkin Lymphoma pipeline drugs market are Bristol-Myers Squibb Co, AstraZeneca Plc, Novartis AG, Gilead Sciences Inc, AbbVie Inc, F. Hoffmann-La Roche Ltd, Gracell Biotechnologies Inc, Pfizer Inc, Bayer AG, and BeiGene Ltd.

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports